Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02463877 · ClinicalTrials.gov registry record · Phase 2
A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02463877: Completed Phase 2 study, sponsored by University of California, San Diego.
NCT02463877 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02463877, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility of surgical techniques involving minimal entry into the living body approach for tumor reduction and treatment in which highly concentrated anticancer drugs are put directly into the abdomen through a tubes (HIPEC), and to determine if this approach may improve short-term postoperative outcomes, including the development of complications related to surgery within the first 30 days after surgery. Participation in this study is entirely voluntary. Approximately 30 subjects will take part in this single-center study and all will be enrolled at University of California San Diego.
Primary Outcome
Rate of postoperative complications within 30 days of surgery: this will be expressed as simple ratio with 95% confidence intervals.
Interventions
- PROCEDURE Minimally-Invasive Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-10 |
| Est. Completion | 2022-04-30 |
| Phase | Phase 2 |
What the finished NCT02463877 record still lists
NCT02463877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Minimally-Invasive Procedure is the first listed.
NCT02463877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02463877 about?
NCT02463877 is a clinical study titled "A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy". The purpose of this study is to determine the feasibility of surgical techniques involving minimal entry into the living body approach for tumor reduction and treatment in which highly concentrated anticancer drugs are put directly into the abdomen through a tubes (HIPEC), and to determine if this a...
What is the current status of trial NCT02463877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2014-10. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT02463877?
The interventions under investigation include: Minimally-Invasive Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT02463877?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02463877's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia